Can Hepatitis B Patients Become Organ Donors?
Yes, patients with hepatitis B virus (HBV) infection can be organ donors, and their organs should be actively considered to expand the donor pool, with appropriate recipient selection and antiviral prophylaxis protocols. 1
Donor Categories and Utilization
The 2015 American Journal of Transplantation consensus guidelines clearly establish that HBV-positive donors fall into two main categories, both of which can be used:
HBsAg-Negative, Anti-HBc-Positive Donors (Resolved/Past Infection)
Organs from these donors should be considered for all adult transplant candidates after individualized risk-benefit assessment and informed consent (strong recommendation, moderate evidence). 1 This represents the most commonly utilized HBV-positive donor category.
- For pediatric candidates, these organs should only be considered in emergent settings in low-prevalence areas 1
- The risk of HBV transmission from anti-HBc+ donors to non-hepatic organ recipients is low (2-3%) 2
- Real-world data confirms safety: a 2021 DTAC analysis showed that only 1 of 21 exposed non-hepatic recipients developed infection from anti-HBc+ donors 3
HBsAg-Positive Donors (Active Chronic Infection)
Organs from HBsAg-positive donors may be carefully considered in all adult transplant candidates after individualized assessment, informed consent, and with specific precautions (weak recommendation, low evidence). 1
Critical requirements for HBsAg+ liver donors:
- Significant donor liver disease must be ruled out by histology before use (strong recommendation) 1
- These donors are increasingly utilized in endemic areas with excellent outcomes 4
Recipient Management Algorithms
For Anti-HBc+ Donors (HBsAg-Negative)
Liver transplant recipients:
- HBV-susceptible recipients (anti-HBc-, anti-HBs-): Indefinite antiviral prophylaxis with lamivudine (most cost-effective) or entecavir/tenofovir (higher resistance barrier) 1
- Vaccine-immune recipients (anti-HBc-, anti-HBs+): Antiviral prophylaxis recommended 1
- Naturally immune recipients (anti-HBc+, anti-HBs+): Prophylaxis not recommended 1
Non-hepatic organ recipients:
- HBsAb-positive recipients generally do not require prophylaxis
- HBsAb-negative recipients should receive lamivudine prophylaxis for 1 year 5
For HBsAg+ Donors
All recipients require:
- Indefinite prophylaxis with entecavir or tenofovir (not lamivudine due to resistance concerns) 1
- HBIG should be considered when anti-HBs titer is <100 IU/L 1
- HBV DNA monitoring every 3 months for 1 year, then every 3-6 months indefinitely 1
Evidence Supporting Safety
Multiple studies demonstrate successful outcomes:
- A 2015 study showed zero HBV transmission in 50 kidney/pancreas recipients from HBcAb+ or HBsAg+ donors using 1-year lamivudine prophylaxis without HBIG 5
- A 2014 Taiwanese study of HBsAg-positive liver grafts showed 77.38% 4-year survival with no HBV reactivation using antiviral monoprophylaxis 4
- A 2020 review confirmed that with appropriate prophylaxis, outcomes for recipients of HBV-positive donors are comparable to uninfected donors 6
Critical Pitfalls to Avoid
Failure to provide prophylaxis: The 2021 DTAC analysis revealed that 6 of 11 liver recipients (54.5%) from HBcAb+ donors who did not receive prophylaxis developed HBV infection—all potentially preventable 3
Premature discontinuation: Two recipients in the DTAC analysis developed infection after prophylaxis was stopped 3
Using lamivudine for HBsAg+ donors: Lamivudine has lower resistance barrier; entecavir or tenofovir are mandatory for HBsAg+ donor organs 1
Inadequate monitoring: HBV DNA should be monitored every 3 months for the first year at minimum 1
Mandatory Consultation
Consultation with a hepatologist or infectious diseases specialist with transplant experience is recommended when considering organs from anti-HBc+ or HBsAg+ donors 1. This ensures proper recipient selection, prophylaxis protocols, and monitoring strategies.
Bottom Line
HBV-positive donors represent a valuable, underutilized resource that can safely expand the donor pool when managed with evidence-based protocols. The key is appropriate recipient selection, mandatory antiviral prophylaxis tailored to donor and recipient HBV status, and rigorous post-transplant monitoring. With modern antiviral therapy, transmission risk is minimal and outcomes are excellent.